参考文献/References:
[1] Haupt H,Baudner S.Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum(author's transl)[J].Hoppe Seylers Z Physiol Chem,1977,358(6):639-646.
[2] Takahashi N,Takahashi Y,Putnam FW.Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum[J].Proc Natl Acad Sci U S A,1985,82(7):1906-1910. DOI:10.1073/pnas.82.7.1906.
[3] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[4] Wang X,Abraham S,McKenzie JAG,et al.LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling[J].Nature,2013,499(7458):306-311.DOI:10.1038/nature12345.
[5] Santibanez JF,Letamendia A,Perez-Barriocanal F,et al.Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling[J].J Cell Physiol,2007,210(2):456-468.DOI:10.1002/jcp.20878.
[6] Hong Q,Zhang L,Fu J,et al.LRG1 promotes diabetic kidney disease progression by enhancing TGF-β-induced angiogenesis[J].J Am Soc Nephrol,2019,30(4):546-562.DOI:10.1681/ASN.2018060599.
[7] Liu JJ,Pek SLT,Ang K,et al.Plasma leucine-rich α-2-glycoprotein 1 predicts rapid eGFR decline and albuminuria progression in type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2017,102(10):3683-3691.DOI:10.1210/jc.2017-00930.
[8] Singh H,Yu Y,Suh MJ,et al.Type 1 diabetes: urinary proteomics and protein network analysis support perturbation of lysosomal function[J].Theranostics,2017,7(10):2704-2717.DOI:10.7150/thno.19679.
[9] Haku S,Wakui H,Azushima K,et al.Early enhanced leucine-rich α-2-glycoprotein-1 expression in glomerular endothelial cells of type 2 diabetic nephropathy model mice[J].Biomed Res Int,2018,2018:2817045.DOI:10.1155/2018/2817045.
[10] Sifuentes-Franco S,Padilla-Tejeda DE,Carrillo-Ibarra S,et al.Oxidative stress, apoptosis, and mitochondrial function in diabetic nephropathy[J].Int J Endocrinol,2018,2018:1875870.DOI:10.1155/2018/1875870.
[11] Sng MK,Chan JSK,Teo Z,et al.Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression[J].Cell Discov,2018,4:15. DOI:10.1038/s41421-018-0014-5.
[12] Tanabe K,Maeshima Y,Sato Y,et al.Antiangiogenic therapy for diabetic nephropathy[J].Biomed Res Int,2017,2017:5724069.DOI:10.1155/2017/5724069.
[13] Kowluru RA,Zhong Q,Santos JM.Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9[J].Expert Opin Investig Drugs,2012,21(6):797-805.DOI:10.1517/13543784.2012.681043.
[14] Kang DH,Hughes J,Mazzali M,et al. Impaired angiogenesis in the remnant kidney model: Ⅱ. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function[J].J Am Soc Nephrol,2001,12(7):1448-1457.
[15] Kang DH,Kim YG,Andoh TF,et al.Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor[J].Am J Physiol Renal Physiol,2001,280(4):F727-F736.DOI:10.1152/ajprenal.2001.280.4.F727.
[16] Fu J,Wei C,Zhang W,et al.Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice[J].Kidney Int,2018,94(2):326-345.DOI:10.1016/j.kint.2018.02.028.
[17] Vallon V,Thomson SC.Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney[J].Annu Rev Physiol,2012,74:351-375.DOI:10.1146/annurev-physiol-020911-153333.
[18] Lee H,Fujimoto M,Ohkawara T,et al.Leucine rich α-2 glycoprotein is a potential urinary biomarker for renal tubular injury[J].Biochem Biophys Res Commun,2018,498(4):1045-1051.DOI:10.1016/j.bbrc.2018.03.111.
[19] Zhang J,Zhu L,Fang J,et al.LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation[J].J Exp Clin Cancer Res,2016,35:29.DOI:10.1186/s13046-016-0306-2.
[20] Hase K,Kanda A,Hirose I,et al.Systemic factors related to soluble(pro)renin receptor in plasma of patients with proliferative diabetic retinopathy[J].PLoS One,2017,12(12):e0189696.DOI:10.1371/journal.pone.0189696.
[21] Chen C,Chen X,Huang H,et al.Elevated plasma and vitreous levels of leucine-rich-α2-glycoprotein are associated with diabetic retinopathy progression[J].Acta Ophthalmol,2019,97(3):260-264.DOI:10.1111/aos.13633.
[22] Pek SL,Tavintharan S,Wang X,et al.Elevation of a novel angiogenic factor, leucine-rich-α2-glycoprotein(LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2015,100(4):1586-1593.DOI:10.1210/jc.2014-3855.
[23] Shinzaki S,Matsuoka K,Iijima H,et al.Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis[J].J Crohns Colitis,2017,11(1):84-91.DOI:10.1093/ecco-jcc/jjw132.
[24] Watson CJ,Ledwidge MT,Phelan D,et al.Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure[J].Circ Heart Fail,2011,4(2):188-197.DOI:10.1161/CIRCHEARTFAILURE.110.952200.
[25] Bos S,Phillips M,Watts GF,et al.Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia[J].J Clin Lipidol,2017,11(3):682-693.DOI:10.1016/j.jacl.2017.03.014.
[26] Kumagai S,Nakayama H,Fujimoto M,et al.Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction[J].Cardiovasc Res,2016,109(2):272-282.DOI:10.1093/cvr/cvv273.
[27] Song W,Wang X.The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure[J].Biophys Rev,2015,7(1):91-104. DOI:10.1007/s12551-014-0158-y.
[28] Meng H,Song Y,Zhu J,et al.LRG1 promotes angiogenesis through upregulating the TGFβ1 pathway in ischemic rat brain[J].Mol Med Rep,2016,14(6):5535-5543.DOI:10.3892/mmr.2016.5925.
[29] Cartier J,Piyasena C,Sparrow SA,et al.Alterations in glucose concentrations affect DNA methylation at Lrg1 in an ex vivo rat cortical slice model of preterm brain injury[J].Eur J Neurosci,2018,47(5):380-387.DOI:10.1111/ejn.13825.
[30] Amer R,Tiosano L,Pe'er J.Leucine-rich α-2-glycoprotein-1(LRG-1)expression in retinoblastoma[J].Invest Ophthalmol Vis Sci,2018,59(2):685-692.DOI:10.1167/iovs.17-22785.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(06):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(06):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(06):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(06):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(06):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(06):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]